The start of the new year brought some changes for the FDA and EMA. In an effort to keep you

March 18, 2020 Hello Everyone,  This is to inform you that Quartesian is closely tracking the Coronavirus (COVID-19) pandemic outbreak

Throughout 2019, Quartesian continues to gain momentum with strong uptake rates for new services and large contract growth. With over

Quartesian is excited to announce a new offering: a suite of clinical trial data pharmacovigilance services. Our services for clinical

Quartesian has entered a multi-year agreement with Medrio, a leading eClinical technology provider, to provide even more high-quality data to

Quartesian, a leading data CRO quickly becoming a clinical data services industry favorite, recently announced a second consecutive year of

In exciting news for Quartesian and their clients, an agreement with Medidata will now provide complete access to the unified Medidata

If you take a look at the most recent issue of Pharma Tech Outlook, you’ll see a familiar face on the

Over the past three years, Quartesian has seen a significant uptick in demand for Medidata RAVE skillsets. To add even

Quartesian’s global footprint is integral to its success as the clinical data FSP of choice for pharmaceuticals, biotech companies, and

As pharmaceutical and biotech innovations continue to gather speed, the clinical research industry demands better models for producing high quality